Professor Paul Harnett

MBBS, FRACP, PhD
Clinical Professor, Sydney Medical School
Director, The Crown Princess Mary Cancer Centre Westmead
Director, Sydney West Cancer Network, Western Sydney & Nepean Blue Mountains Local Health Districts
Senior Staff Specialist, Medical Oncology, Westmead Hospital

Telephone +61 2 9845 6432
Fax +61 2 9891 6035

Map

Biographical details

Professor Paul Harnett is a medical oncologist who specialises in the management of breast cancer and gynaecological cancers, particularly ovarian cancer. He is a senior clinician-scientist with over 25 years experience in observing, studying, and treating ovarian cancers. His research interests include understanding the causes of and treatment options for ovarian cancer. He has a national and international reputation in the field and has co-authored NHMRC guidelines for ovarian cancer. Professor Harnett is Director of The Crown Princess Mary Cancer Centre Westmead, a comprehensive cancer care centre with an international reputation in clinical cancer care, teaching and cancer research. Additionally, as Director of Sydney West Cancer Network he oversees a collaborative network of clinical cancer services across Sydney’s west including the development of localised subspecialty cancer services which ensures each patient has access to tertiary level cancer wherever he/she lives in Sydney’s west. Professor Harnett also is a key facilitator of translational research as head of the Sydney West Translational Cancer Research Centre, a consortium linking the multi-disciplinary groups involved in cancer care and (clinical and basic) cancer research in western Sydney. Professor Harnett notes, “I am interested firstly in turning clinical observations into research questions that help explain the observations and facilitate improved clinical care. My second interest is bringing people together to help establish multidisciplinary tumour programs from a systems perspective. The aim is to create programs specific for each type of cancer, which would methodically encapsulate the patient’s experience, from screening and diagnosis through to multidisciplinary treatment, psychosocial care and palliative care. The idea is to develop better systems that improve patient outcomes”.

Research interests

Professor Harnett has had a long-standing interest in understanding the mechanism underlying how cancers become resistant to chemotherapy, having studied this for over 20 years in numerous cancers with a special interest in ovarian cancer. His team is studying genes that may be implicated in sensitivity/resistance of ovarian cancer to chemotherapy. Professor Harnett holds a patent in Australia and the USA on therapeutic application of a gene involved in determining sensitivity to chemotherapy in ovarian cancer.

Professor Harnett also conducts clinical research including Phase 1 and 2 clinical trials testing new therapeutic agents or regimens for ovarian cancer (e.g. two international trials of MEK inhibition (MEK162 and pimasertib) in Low Grade Serous Carcinoma). Additionally, with his large and active clinical practice in ovarian cancer, he has assembled a (continually accruing) significant cohort of patients for drug and translational studies, with many having had sequential biopsies at multiple points of disease. As the distinct clinical behaviour and biology of subsets of ovarian cancers becomes more apparent, the clinical observations are being translated into research questions, e.g. is there an underlying genetic basis differentiating the extremes of response to ovarian cancer therapy observed in practice (i.e. extremely good responders vs those refractory to treatment)?

Selected grants

2015

  • INOVATe - Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care; deFazio A, Harnett P, Friedlander M, Balleine R, Bowtell D, Samimi G, Wain G, Hacker N, Marsh D, Beale P; Cancer Institute New South Wales/Translational Program Grant.

2013

  • Early detection of chemotherapy-related cardiotoxicity; Thomas L, Richards D, Harnett P; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Molecular markers of relapse and treatment response in ovarian cancer; deFazio A, Harnett P, Bowtell D; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • Sydney-West Translational Cancer Research Centre; Harnett P; Cancer Institute New South Wales/Translational Health Services Research Grant.

2010

  • Response to Chemotherapy in Ovarian Cancer; deFazio A, Gurney H, Chenevix-Trench G, Haber M, Gurney H, Harnett P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Genomic determinants of chemosensitivity in ovarian cancer; deFazio A, Bowtell D, Harnett P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Phase 2 study of aromatase inhibitors in women with potentially hormone sensitive recurrent metatastic gynaecological neoplasms:PARAGON; Friedlander M, Vaughan M, Quinn M, McCarthy N, Vaughan M, Harnett P, Gainford M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Pathways of malignant progression in ovarian cancer; deFazio A, Bowtell D, Harnett P, Hogg R, Russell P; Cancer Council New South Wales/Research Project Grants.
  • Breast cancer biospecimen resource; Morey A, Forbes J, Scott R, Spigelman A, Clarke C, Kefford R, Baxter R, Marsh D, Friedlander M, Harnett P, Balleine R, Bilous M, Boyages J, Sutherland R; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2009

  • Certain death in uncertain time: a qualitative study of the experience of advanced overian cancer; Harnett P, Kerridge I, Mason C, Jordens C, Hobbs K; Millennium Foundation Ltd/Research Support.

2007

  • Chemo-sensitising pathways in ovarian cancer; Russell P, deFazio A, Harnett P, Russell P; Cancer Council New South Wales/Research Project Grants.

2006

  • Certain death in uncertain time: a qualitative study of the experience of advanced overian cancer; Harnett P, Kerridge I, Mason C, Jordens C, Hobbs K; National Health and Medical Research Council (NHMRC)/Project Grants.

2005

  • Breast cancer biospecimen resource; Marsh D, Clarke C, Harnett P, Spigelman A, Forbes J, Harnett P, Friedlander M, Sutherland R, Boyages J, Morey A, Spigelman A, Scott R, Balleine R, Baxter R, Bilous M, Kefford R; Cancer Institute New South Wales/Research Grant.

2004

  • Breast cancer biospecimen resource; Clarke C, Balleine R, Bilous M, Kefford R, Baxter R, Harnett P, Spigelman A, Forbes J, Spigelman A, Marsh D, Boyages J, Friedlander M, Harnett P, Morey A, Scott R, Sutherland R; National Health and Medical Research Council (NHMRC)/Enabling Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Hedditch, E., Gao, B., Russell, A., Li, Y., Emmanuel, C., Beesley, J., Johnatty, S., Chen, X., Harnett, P., George, J., deFazio, A., et al (2014). ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. Journal of the National Cancer Institute, 106(7), 1-11. [More Information]
  • Emmanuel, C., Chiew, Y., George, J., Etemadmoghadam, D., Anglesio, M., Sharma, R., Russell, P., Kennedy, C., Fereday, S., Hung, J., Hogg, R., Wain, G., Brand, A., Balleine, R., Clarke, C., Harnett, P., deFazio, A., et al (2014). Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clinical Cancer Research, 20(24), 6618-6630. [More Information]
  • Gao, B., Russell, A., Beesley, J., Chen, X., Healey, S., Henderson, M., Wong, K., Emmanuel, C., Galletta, L., Johnatty, S., Harnett, P., Balleine, R., deFazio, A., et al (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 4, 1-9. [More Information]
  • Gupta, S., Taylor, N., Selvakumar, D., Harnett, P., Wilcken, N., Lee, C. (2014). Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to Westmead Hospital. Internal Medicine Journal, 44(12a), 1235-1239. [More Information]
  • Ojaimi, S., Harnett, P., Fulcher, D. (2014). Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. The Journal of Allergy and Clinical Immunology: In Practice, 2(1), 105-106. [More Information]
  • Fotopoulou, C., Vergote, I., Mainwaring, P., Bidziński, M., Vermorken, J., Ghamande, S., Harnett, P., Del Prete, S., Green, J., Spaczyński, M., et al (2014). Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Annals of Oncology, 25(1), 160-165. [More Information]
  • Stoodley, P., Richards, D., Boyd, A., Hui, R., Harnett, P., Meikle, S., Clarke, J., Thomas, L. (2013). Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. European Heart Journal - Cardiovascular Imaging, 14(3), 228-234. [More Information]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 11(1), 1-10. [More Information]
  • Stoodley, P., Richards, D., Boyd, A., Hui, R., Harnett, P., Meikle, S., Byth Wilson, K., Stuart, K., Clarke, J., Thomas, L. (2013). Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. European Journal of Cancer, 49(16), 3396-3403. [More Information]
  • Harnett, P. (2012). All pains are equal, but some seem more urgent than others. The Lancet, 380(9836), 28-28. [More Information]
  • Harnett, P., Kerridge, I., Jordens, C., Hobbs, K., Mason, C., Morrell, B. (2012). Beyond evidence: reappraising use of CA-125 as post-therapy surveillance for ovarian cancer. Medical Journal of Australia, 196(7), 440-441. [More Information]
  • Cohen, S., Reid, S., Pixton, S., Harnett, P., Condous, G. (2012). Choriocarcinoma of the lung masquerading as a persisting pregnancy of unknown location (PUL). Australian and New Zealand Journal of Obstetrics and Gynaecology, 52(2), 211-212. [More Information]
  • Cowin, P., George, J., Fereday, S., Loehrer, E., Van Loo, P., Cullinane, C., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M., Harnett, P., deFazio, A., et al (2012). LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 72(16), 4060-4073. [More Information]
  • Morrell, B., Jordens, C., Kerridge, I., Harnett, P., Hobbs, K., Mason, C. (2012). The perils of a vanishing cohort: A study of social comparisons by women with advanced ovarian cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 21(4), 382-391. [More Information]
  • Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PloS One, 6(3), e17617-1-e17617-18. [More Information]
  • Pharoah, P., Palmieri, R., Ramus, S., Gayther, S., Andrulis, I., Anton-Culver, H., Antonenkova, N., Antoniou, A., Goldgar, D., deFazio, A., Gao, B., Harnett, P., et al (2011). The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 17(11), 3742-3750. [More Information]
  • Stoodley, P., Richards, D., Hui, R., Boyd, A., Harnett, P., Meikle, S., Clarke, J., Thomas, L. (2011). Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. European Journal of Echocardiography, 12, 945-952. [More Information]
  • Jordens, C., Morrell, B., Harnett, P., Hobbs, K., Mason, C., Kerridge, I. (2010). Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer. Social Science and Medicine, 71(9), 1548-1556. [More Information]
  • Dear, R., Gao, B., Harnett, P. (2010). Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia-Pacific Journal of Clinical Oncology, 6(1), 66-73. [More Information]
  • Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M., Harnett, P., Chiew, Y., et al (2009). Integrated genome-wide DMA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research, 15(4), 1417-1427. [More Information]
  • Johnatty, S., Beesley, J., Paul, J., Fereday, S., Spurdle, A., Webb, P., Byth, K., Marsh, S., McLeod, H., AOCS, S., Harnett, P., deFazio, A., et al (2008). ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clinical Cancer Research, 14(17), 5594-5601. [More Information]
  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]
  • Friedlander, M., Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., Harnett, P. (2007). Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal Of Gynecological Cancer, 17(2), 350-358. [More Information]
  • Harnett, P., Buck, M., Beale, P., Goldrick, A., Allan, S., Fitzharris, B., De Souza, P., Links, M., Kalimi, G., Davies, T., et al (2007). Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. International Journal Of Gynecological Cancer, 17(2), 359-366. [More Information]
  • Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 100(2), 239-246. [More Information]
  • Sorensen, R., Lloyd, A., Van Kemenade, C., Harnett, P. (2005). Managing quality in cancer services: why improvement isn't easy. Australian Health Review, 29(4), 406-415.
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]
  • Rischin, D., Phillips, K., Friedlander, M., Harnett, P., Quinn, M., Richardson, G., Martin, A. (2004). A Phase II Trial Of Capecitabine In Heavily Pre-Treated Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 93(2), 417-421.
  • Choi, J., Harnett, P., Fulcher, D. (2004). Carboplatin desensitization. Annals of Allergy, Asthma, and Immunology, 93(2), 137-141.
  • Choi, J., Harnett, P., Fulcher, D. (2004). Carboplatin Desensitization. Annals of Allergy, Asthma, and Immunology, 93(2), 137-141.
  • Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004). Expression Of Progesterone Receptor A And B Isoforms In Low-Grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 23(2), 138-144.
  • Shannon, C., Kirk, J., Barnetson, R., Evans, J., Schnitzler, M., Quinn, M., Hacker, N., Crandon, A., Harnett, P. (2003). Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clinical Cancer Research, 9(4), 1387-1392.
  • Guminski, A., Harnett, P., deFazio, A. (2002). Scientists and clinicians test their metal - back to the future with platinum compounds. Lancet Oncology, 3(5), 312-318.
  • King, M., Hall, J., Harnett, P. (2001). A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. Medical Journal of Australia, 174(6), 312.
  • Harnett, P., Moynihan, T. (2001). But doctor, what have i got to lose..? Journal of Clinical Oncology, 19(13), 3294-3296.
  • Guminski, A., Harnett, P., deFazio, A. (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 48(3), 229-234.
  • Guminski, A., deFazio, A., Harnett, P. (2001). New genetics and cancer chemotherapy. Today's Life Science (Australia), 13(2), 36-40.
  • Hassett, G., Harnett, P., Manolios, N. (2001). Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clinical and Experimental Rheumatology, 19, 197-200.
  • Harnett, P. (2001). Should doctors wear white coats. Medical Journal of Australia, 174(7), 343-344.
  • King, M., Hall, J., Caleo, S., Gurney, H., Harnett, P. (2000). Home or Hospital? An evaluation of the costs, preferences and outcomes of domiciliary chemotherapy. International Journal of Health Services, 30(3), 557-579.

Patents

  • deFazio, A., Harnett, P., Guminski, A. (2005). Patent Families: Determinants of sensitivity to chemotherapeutic agents. Patent No. 2005316200.

2014

  • Hedditch, E., Gao, B., Russell, A., Li, Y., Emmanuel, C., Beesley, J., Johnatty, S., Chen, X., Harnett, P., George, J., deFazio, A., et al (2014). ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. Journal of the National Cancer Institute, 106(7), 1-11. [More Information]
  • Emmanuel, C., Chiew, Y., George, J., Etemadmoghadam, D., Anglesio, M., Sharma, R., Russell, P., Kennedy, C., Fereday, S., Hung, J., Hogg, R., Wain, G., Brand, A., Balleine, R., Clarke, C., Harnett, P., deFazio, A., et al (2014). Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clinical Cancer Research, 20(24), 6618-6630. [More Information]
  • Gao, B., Russell, A., Beesley, J., Chen, X., Healey, S., Henderson, M., Wong, K., Emmanuel, C., Galletta, L., Johnatty, S., Harnett, P., Balleine, R., deFazio, A., et al (2014). Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 4, 1-9. [More Information]
  • Gupta, S., Taylor, N., Selvakumar, D., Harnett, P., Wilcken, N., Lee, C. (2014). Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to Westmead Hospital. Internal Medicine Journal, 44(12a), 1235-1239. [More Information]
  • Ojaimi, S., Harnett, P., Fulcher, D. (2014). Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. The Journal of Allergy and Clinical Immunology: In Practice, 2(1), 105-106. [More Information]
  • Fotopoulou, C., Vergote, I., Mainwaring, P., Bidziński, M., Vermorken, J., Ghamande, S., Harnett, P., Del Prete, S., Green, J., Spaczyński, M., et al (2014). Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Annals of Oncology, 25(1), 160-165. [More Information]

2013

  • Stoodley, P., Richards, D., Boyd, A., Hui, R., Harnett, P., Meikle, S., Clarke, J., Thomas, L. (2013). Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. European Heart Journal - Cardiovascular Imaging, 14(3), 228-234. [More Information]
  • Carus, A., Gurney, H., Gebski, V., Harnett, P., Hui, R., Kefford, R., Wilcken, N., Ladekarl, M., von der Maase, H., Donskov, F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 11(1), 1-10. [More Information]
  • Stoodley, P., Richards, D., Boyd, A., Hui, R., Harnett, P., Meikle, S., Byth Wilson, K., Stuart, K., Clarke, J., Thomas, L. (2013). Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. European Journal of Cancer, 49(16), 3396-3403. [More Information]

2012

  • Harnett, P. (2012). All pains are equal, but some seem more urgent than others. The Lancet, 380(9836), 28-28. [More Information]
  • Harnett, P., Kerridge, I., Jordens, C., Hobbs, K., Mason, C., Morrell, B. (2012). Beyond evidence: reappraising use of CA-125 as post-therapy surveillance for ovarian cancer. Medical Journal of Australia, 196(7), 440-441. [More Information]
  • Cohen, S., Reid, S., Pixton, S., Harnett, P., Condous, G. (2012). Choriocarcinoma of the lung masquerading as a persisting pregnancy of unknown location (PUL). Australian and New Zealand Journal of Obstetrics and Gynaecology, 52(2), 211-212. [More Information]
  • Cowin, P., George, J., Fereday, S., Loehrer, E., Van Loo, P., Cullinane, C., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M., Harnett, P., deFazio, A., et al (2012). LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 72(16), 4060-4073. [More Information]
  • Morrell, B., Jordens, C., Kerridge, I., Harnett, P., Hobbs, K., Mason, C. (2012). The perils of a vanishing cohort: A study of social comparisons by women with advanced ovarian cancer. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 21(4), 382-391. [More Information]

2011

  • Emmanuel, C., Gava, N., Kennedy, C., Balleine, R., Sharma, R., Wain, G., Brand, A., Hogg, R., Etemadmoghadam, D., George, J., Clarke, C., Harnett, P., deFazio, A., et al (2011). Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PloS One, 6(3), e17617-1-e17617-18. [More Information]
  • Pharoah, P., Palmieri, R., Ramus, S., Gayther, S., Andrulis, I., Anton-Culver, H., Antonenkova, N., Antoniou, A., Goldgar, D., deFazio, A., Gao, B., Harnett, P., et al (2011). The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 17(11), 3742-3750. [More Information]
  • Stoodley, P., Richards, D., Hui, R., Boyd, A., Harnett, P., Meikle, S., Clarke, J., Thomas, L. (2011). Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. European Journal of Echocardiography, 12, 945-952. [More Information]

2010

  • Jordens, C., Morrell, B., Harnett, P., Hobbs, K., Mason, C., Kerridge, I. (2010). Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer. Social Science and Medicine, 71(9), 1548-1556. [More Information]
  • Dear, R., Gao, B., Harnett, P. (2010). Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia-Pacific Journal of Clinical Oncology, 6(1), 66-73. [More Information]

2009

  • Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M., Harnett, P., Chiew, Y., et al (2009). Integrated genome-wide DMA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research, 15(4), 1417-1427. [More Information]

2008

  • Johnatty, S., Beesley, J., Paul, J., Fereday, S., Spurdle, A., Webb, P., Byth, K., Marsh, S., McLeod, H., AOCS, S., Harnett, P., deFazio, A., et al (2008). ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clinical Cancer Research, 14(17), 5594-5601. [More Information]
  • Scurr, L., Guminski, A., Chiew, Y., Balleine, R., Sharma, R., Lei, Y., Pryor, K., Wain, G., Brand, A., Byth, K., Kennedy, C., Rizos, H., Harnett, P., deFazio, A. (2008). Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 14(21), 6924-6932. [More Information]

2007

  • Friedlander, M., Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., Harnett, P. (2007). Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal Of Gynecological Cancer, 17(2), 350-358. [More Information]
  • Harnett, P., Buck, M., Beale, P., Goldrick, A., Allan, S., Fitzharris, B., De Souza, P., Links, M., Kalimi, G., Davies, T., et al (2007). Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. International Journal Of Gynecological Cancer, 17(2), 359-366. [More Information]

2006

  • Guminski, A., Balleine, R., Chiew, Y., Webster, L., Tapner, M., Farrell, G., Harnett, P., deFazio, A. (2006). MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 100(2), 239-246. [More Information]

2005

  • deFazio, A., Harnett, P., Guminski, A. (2005). Patent Families: Determinants of sensitivity to chemotherapeutic agents. Patent No. 2005316200.
  • Sorensen, R., Lloyd, A., Van Kemenade, C., Harnett, P. (2005). Managing quality in cancer services: why improvement isn't easy. Australian Health Review, 29(4), 406-415.
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]

2004

  • Rischin, D., Phillips, K., Friedlander, M., Harnett, P., Quinn, M., Richardson, G., Martin, A. (2004). A Phase II Trial Of Capecitabine In Heavily Pre-Treated Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 93(2), 417-421.
  • Choi, J., Harnett, P., Fulcher, D. (2004). Carboplatin desensitization. Annals of Allergy, Asthma, and Immunology, 93(2), 137-141.
  • Choi, J., Harnett, P., Fulcher, D. (2004). Carboplatin Desensitization. Annals of Allergy, Asthma, and Immunology, 93(2), 137-141.
  • Balleine, R., Earls, P., Webster, L., Mote, P., deFazio, A., Harnett, P., Clarke, C. (2004). Expression Of Progesterone Receptor A And B Isoforms In Low-Grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 23(2), 138-144.

2003

  • Shannon, C., Kirk, J., Barnetson, R., Evans, J., Schnitzler, M., Quinn, M., Hacker, N., Crandon, A., Harnett, P. (2003). Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium. Clinical Cancer Research, 9(4), 1387-1392.

2002

  • Guminski, A., Harnett, P., deFazio, A. (2002). Scientists and clinicians test their metal - back to the future with platinum compounds. Lancet Oncology, 3(5), 312-318.

2001

  • King, M., Hall, J., Harnett, P. (2001). A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. Medical Journal of Australia, 174(6), 312.
  • Harnett, P., Moynihan, T. (2001). But doctor, what have i got to lose..? Journal of Clinical Oncology, 19(13), 3294-3296.
  • Guminski, A., Harnett, P., deFazio, A. (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 48(3), 229-234.
  • Guminski, A., deFazio, A., Harnett, P. (2001). New genetics and cancer chemotherapy. Today's Life Science (Australia), 13(2), 36-40.
  • Hassett, G., Harnett, P., Manolios, N. (2001). Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clinical and Experimental Rheumatology, 19, 197-200.
  • Harnett, P. (2001). Should doctors wear white coats. Medical Journal of Australia, 174(7), 343-344.

2000

  • King, M., Hall, J., Caleo, S., Gurney, H., Harnett, P. (2000). Home or Hospital? An evaluation of the costs, preferences and outcomes of domiciliary chemotherapy. International Journal of Health Services, 30(3), 557-579.

To update your profile click here. For support on your academic profile contact .